Thursday, 23 September 2021

Promethera explores therapies for liver diseases in China

21 July 2020 | News

Plans to Form Joint Venture with Hao Tian Development Group Limited

Image credit-

Image credit-

Belgium based Promethera Biosciences S.A., global innovator in cell-based medicines and liver diseases, and Hao Tian Development Group Limited, a diversified investment holding company, through its subsidiary Aceso Life Science Holding Limited have announced that the companies have entered into an agreement to form a joint venture.

Aceso and Promethera® hold 60% and 40% of the equity in the Joint Venture Company, respectively. The Joint Venture Company is vested with the exclusive right to develop, register, distribute and commercialize Promethera®'s therapeutic products (cell therapies and antibodies developed by Promethera® Group) in China and Southeast Asia.

Indications in which the products will be deployed include; Acute-on-Chronic Liver Failure (ACLF), Non-Alcoholic Steatohepatitis (NASH), Urea Cycle Disorder (UCD), liver cirrhosis and various autoimmune diseases and cancers.

Promethera® will manufacture and supply the therapeutic products, and provide ongoing technical support during development and commercialization. The Joint Venture Company will seek opportunities for cooperation with Itochu Corporation.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account